2007: Clinical Osteoporosis and Metabolic Bone Disease II
Search or Browse by Day

Clinical Osteoporosis and Metabolic Bone Disease II

Saturday, November 10, 2007
1544
Comparable Adherence Between Monthly Oral and Quarterly Intravenous Ibandronate in Patients Who Discontinued Previous Bisphosphonates because of Gastrointestinal Intolerance
1545
Tolerability of Monthly Ibandronate and Weekly Alendronate in Women With Postmenopausal Osteoporosis: Results From the MOTION Study
1546
Rapid Suppression of Serum CTX within Three Days of Treatment Initiation with Montly Oral Ibandronate
1547
Oral Ibandronate (150mg) Administered Monthly Provides Similar Improvements in Hip Bone Mineral Density as Oral Alendronate (70mg) Administered Weekly in Postmenopausal Osteoporosis
1548
Treatment With Intravenous Pamidronate is a Good Alternative For Oral Bisphosphonates in Case of Gastrointestinal Side Effects or Contraindications
1549
Bone Metabolism in Primary Senile Osteoporosis. Effects of Two Different Calcium Supplementation
1550
High Dose Oral Vitamin D3 in Rheumatologic Patients with Severe Vitamin D Deficiency
1551
Management Scheme for Glucocorticoid-Induced Osteoporosis (gio) in Rheumatoid Arthritis (ra) Based on a Two-Year Longitudinal Cohort Study
1552
How Quickly Do Oral Bisphosphonates Work, and are There Differences between Them?
1553
Identifying Clinical Vertebral Fractures Using Administrative Claims Data: A Validation Study
1554
Longitudinal Patterns of Adherence with Bisphosphonates
1555
Comparative Gastrointestinal Safety of Weekly Oral Bisphosphonates for the Treatment of Osteoporosis
1556
Improved Persistence at 12 Months with Monthly Bisphosphonate Therapy Compared to Weekly Bisphosphonates: Results from Two Retrospective Databases
1557
Undertreatment with Anti-Osteoporotic Drugs after Hip Fracture
1558
A Beneficial Roll of Etanercept on Bone Metabolism
1559
Prevalence with Seasonal Variation of Hypovitaminosis D, and Male Hypogonadism, in Prednisone-treated Patients with Rheumatic Disease
1560
Association of Low Levels of 25 Hydroxyvitamin D and Moderate/Severe Vertebral Fractures in Community-Dwelling Elderly Women
1561
High Prevalence of Vertebral Fractures in Epileptic Patients Taking Anti-Epileptic Drugs
1562
Prevalence of Osteoporosis and Risk Factors for Low Energy Hip Fracture in Southern Norway
1563
Correlation of Isokinetic Knee and Trunk Muscular Strength with Bone Mineral Content in Female Soccer Players
1564
Bisphosphonate Use Increases in Patients at High Risk for Fracture Following an Integrated Osteoporosis Educational Intervention: Canadian Quality Circle (CQC) National Project
1565
The Impact of Incident Fractures on Health Related Quality of Life Depends on Fracture Site: The Canadian Multicentre Osteoporosis Study (CaMos)
1566
An Osteoporosis Educational Intervention Increases the use of X-ray Ordering in High Risk Patients with Height Loss or Kyphosis: Canadian Quality Circle (CQC) National Project
1567
Validation of the Osteoporosis Self-Assessment Tool in Men with Rheumatoid Arthrtis
1568
Bone Mineral Density, Anti-histamine Therapy, and Proton Pump Inhibitors : An Analysis of NHANES III
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>